The purpose of this study was to assess the ability of metabolic parameters, radiomic features, PET-CT, and clinicopathological data to detect EGFR, BRAF, and KRAS mutation status in metastatic colorectal cancer patients (mCRC). The gene discussed is EGFR; the disease is metastatic colorectal cancer.